BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36387507)

  • 21. Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients.
    Tang C; Zhu L; Zhang L; Tan C; Peng Z; Liu B; Liu W; Hu H; Bai Y; Wang B; Lin L; Liang J; Li X; Guo Y; Liu Y
    Clin Chim Acta; 2020 Nov; 510():88-96. PubMed ID: 32645388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
    Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
    Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
    Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR.
    Iwama E; Takayama K; Harada T; Okamoto I; Ookubo F; Kishimoto J; Baba E; Oda Y; Nakanishi Y
    Oncotarget; 2015 Aug; 6(24):20466-73. PubMed ID: 26015401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
    Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
    J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients.
    Chan DLH; Toh GLX; Goh LL
    Exp Mol Pathol; 2020 Oct; 116():104515. PubMed ID: 32738312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Droplet Digital PCR as a Molecular Tool for the Detection of the
    Durgut S; Salihefendić L; Pećar D; Čeko I; Mulahuseinović N; Izmirlija M; Konjhodžić R
    Balkan J Med Genet; 2023 Dec; 26(2):21-26. PubMed ID: 38482255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.
    Kim B; Kim Y; Shin S; Lee ST; Cho JY; Lee KA
    Cancer Cell Int; 2022 Feb; 22(1):82. PubMed ID: 35168603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer.
    Crucitta S; Ruglioni M; Novi C; Manganiello M; Arici R; Petrini I; Pardini E; Cucchiara F; Marmorino F; Cremolini C; Fogli S; Danesi R; Del Re M
    Clin Chim Acta; 2023 Feb; 541():117239. PubMed ID: 36736684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of epidermal growth factor receptor gene mutations in different types of non-small cell lung cancer by droplet digital PCR and amplification refractory mutation system].
    Li R; Ye SB; He Y; Wang X; Wu N; Xia QY; Shen Q; Shi SS
    Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):764-768. PubMed ID: 29136689
    [No Abstract]   [Full Text] [Related]  

  • 33. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients.
    Hackner K; Buder A; Hochmair MJ; Strieder M; Grech C; Fabikan H; Burghuber OC; Errhalt P; Filipits M
    Clin Med Insights Oncol; 2021; 15():1179554921993072. PubMed ID: 33642890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development, validation, and comparison of gene analysis methods for detecting
    Hanibuchi M; Kanoh A; Kuramoto T; Saito T; Tobiume M; Saijo A; Kozai H; Kondo M; Morizumi S; Yoneda H; Kagawa K; Ogino H; Sato S; Kawano H; Otsuka K; Toyoda Y; Nokihara H; Goto H; Nishioka Y
    Oncotarget; 2019 Jun; 10(38):3654-3666. PubMed ID: 31217900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
    Watanabe M; Kawaguchi T; Isa S; Ando M; Tamiya A; Kubo A; Saka H; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Sakamoto K; Matsumura A; Koh Y
    Clin Cancer Res; 2015 Aug; 21(15):3552-60. PubMed ID: 25882755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons learned from routine, targeted assessment of liquid biopsies for
    Mondaca S; Offin M; Borsu L; Myers M; Josyula S; Makhnin A; Shen R; Riely GJ; Rudin CM; Ladanyi M; Yu HA; Li BT; Arcila ME
    Acta Oncol; 2019 Nov; 58(11):1634-1639. PubMed ID: 31347936
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
    Ntzifa A; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.